Exact Sciences Corp. (NYSE:EXAS) on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ...

NasdaqCM:EXAS 1 Year Share Price vs Fair Value Explore Exact Sciences's Fair Values from the Community and select ...

Exact Sciences secures colorectal cancer test rights from Freenome in a $75M agreement with up to $700M milestone payouts.

Q2 2025 Earnings Call Transcript August 6, 2025 Exact Sciences Corporation beats earnings expectations. Reported EPS is $0.22 ...

The layoffs come despite CEO Kevin Conroy telling investors the company had just completed an “unbelievable quarter” for the ...

Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...

Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm ...

Exact Sciences stock crashed Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer ...

Full-year 2025 revenue and adjusted EBITDA guidance were raised, reflecting strong commercial execution and new product launches. These 10 stocks could mint the next wave of millionaires › Exact ...

Exact Sciences is laying off 4% of its overall workforce, including 80 positions at the headquarters in Madison.

Exact Sciences (EXAS) delivered earnings and revenue surprises of +1,200.00% and +4.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Exact Sciences’ gross margin for the quarter was 69%, with adjusted gross margin at 72%. The company reported operating cash flow of $89 million and free cash flow of $47 million, ending the quarter ...